| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Nitric oxide |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Formoterol fumarate |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Ipratropium (substance) |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Sympathomimetic agent (substance) |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| respirationsmuskelrelakserende middel |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| koffein og natriumbenzoat injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Forgiftning med bronkodilator-lægemiddel |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| accidentel forgiftning med bronkodilator-lægemiddel |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| tilsigtet forgiftning med bronkodilator-lægemiddel |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Forgiftning med bronkodilator-lægemiddel, uvist med hvilken hensigt |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Bronchodilator preparations adverse reaction |
Causative agent |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| allergi over for bronchodilatorpræparater |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Bronchodilator preparations overdose |
Causative agent |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Accidental bronchodilator preparations overdose |
Causative agent |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Intentional bronchodilator preparations overdose |
Causative agent |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| overdosis af bronkodilatatorpræparater, uvist med hvilken hensigt |
Causative agent |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Anticholinergic bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| xanthinbronchodilatorer |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Compound bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing xanthine (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| bronkodilatorpræparat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| caffein 5 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| caffeincitrat 20 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/2mg suppository (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing formoterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + caffein + orphenadrincitrat tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Oxitropium (substance) |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing leukotriene receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing fluticasone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg blisterplader + diskhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 100 µg blisterplader + diskhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 250 µg blisterplader + diskhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg blisterplader til genopfyldning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 100 µg blisterplader til genopfyldning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 250 µg blisterplader til genopfyldning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 25 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 125 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 250 µg inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 500 µg blisterplader + diskhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 500 µg blisterplader til genopfyldning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg indåndingsudløst tørpulverinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 100 µg indåndingsudløst tørpulverinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 250 µg indåndingsudløst tørpulverinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 500 µg indåndingsudløst tørpulverinhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 0,5 mg/2 ml nebulisatorampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 2 mg/2 ml nebulisatorampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 125 µg CFC-fri inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 250 µg CFC-fri inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg CFC-fri inhalator |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 50 µg vandig næsespray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticasonpropionat 400 µg næsedråber til engangsbrug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 500 microgram/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50 microgram/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticason til respirationssystemet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone-containing product in nasal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| fluticason til topikal anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| respirationsmuskelrelakserende middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate [respiratory use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone [nose] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate[skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| dyphyllin 125 mg/ml injektionsvæske, opløsning, ampul a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| dyphyllin 160 mg/15 ml eliksir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 1.2 gram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| guaifenesin 50 mg/1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| guaifenesin 400 mg/10 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 800 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| guaifenesin 100 mg/5 ml oral væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| dyphyllin 100 mg/15 ml eliksir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Diprophylline 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Diprophylline 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 50 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 1 g oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
FHIR